Proactiveinvestors United Kingdom RNS press releases https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom RNS press releases RSS feed en Sun, 08 Dec 2019 16:10:14 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000297830-en Fri, 06 Dec 2019 12:00:00 +0000 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000297830-en <![CDATA[RNS press release - Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000291979-en Wed, 06 Nov 2019 12:00:00 +0000 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000291979-en <![CDATA[RNS press release - Summit Therapeutics Recognises C. difficile Awareness Month ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000291449-en Mon, 04 Nov 2019 12:00:00 +0000 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000291449-en <![CDATA[RNS press release - Summit Therapeutics to Present at the 2019 BIO Investor Forum ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000288177-en Wed, 16 Oct 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000288177-en <![CDATA[RNS press release - Directorate change ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000287552-en Fri, 11 Oct 2019 12:01:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000287552-en <![CDATA[RNS press release - Half-year report ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000287548-en Fri, 11 Oct 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000287548-en <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000287411-en Thu, 10 Oct 2019 14:30:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000287411-en <![CDATA[RNS press release - Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000286636-en Mon, 07 Oct 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000286636-en <![CDATA[RNS press release - Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000276220-en Thu, 03 Oct 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000276220-en <![CDATA[RNS press release - Block Listing Six Month Review ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000276105-en Thu, 03 Oct 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000276105-en <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/LSE20191001140551_14249423 Tue, 01 Oct 2019 14:05:51 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/LSE20191001140551_14249423 <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/LSE20191001140044_14249407 Tue, 01 Oct 2019 14:00:44 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/LSE20191001140044_14249407 <![CDATA[RNS press release - Summit Therapeutics to Host R&D Day 7 October 2019 ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000274277-en Wed, 25 Sep 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000274277-en <![CDATA[RNS press release - Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000274275-en Tue, 24 Sep 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000274275-en <![CDATA[RNS press release - Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000273269-en Wed, 18 Sep 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000273269-en <![CDATA[RNS press release - Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000261002-en Thu, 05 Sep 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000261002-en <![CDATA[RNS press release - Summit Therapeutics to Participate in Upcoming Investor Conferences ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000260803-en Wed, 04 Sep 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000260803-en <![CDATA[RNS press release - Summit Therapeutics to Present at the Canaccord Genuity Growth Conference ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000254918-en Thu, 01 Aug 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000254918-en <![CDATA[RNS press release - Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000252797-en Wed, 17 Jul 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000252797-en <![CDATA[RNS press release - Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia ]]> https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000251455-en Tue, 09 Jul 2019 12:00:00 +0100 https://www.proactiveinvestors.co.uk/LON:SUMM/Summit-Therapeutics-PLC/rns/NASDAQ_1000251455-en